Table 2

Lipid, body weight, and BP responses to treatment at Week 14

ParameterPlaceboMK-0941 dose (mg t.i.d. a.c.)
10203040
n111 to 114112 to 118113 to 117113 to 117113 to 118
Total cholesterol
 % Change from baseline4.3 (1.2 to 7.4)4.7 (1.5 to 7.9)6.2 (3.1 to 9.4)5.1 (1.9 to 8.3)7.4 (4.2 to 10.5)
 Change from placebo0.4 (−4.0 to 4.7)1.9 (−2.4 to 6.2)0.8 (−3.5 to 5.1)3.0 (−1.3 to 7.4)
LDL cholesterol
 % Change from baseline7.8 (3.2 to 12.4)2.6 (−2.2 to 7.5)5.6 (0.8 to 10.3)5.5 (0.7 to 10.2)5.5 (0.7 to 10.3)
 Change from placebo−5.2 (−11.7 to 1.4)−2.2 (−8.7 to 4.3)−2.3 (−8.8 to 4.2)−2.3 (−8.9 to 4.3)
HDL cholesterol
 % Change from baseline−0.2 (−2.9 to 2.5)2.3 (−0.5 to 5.1)−0.1 (−2.8 to 2.6)−0.9 (−3.7 to 1.8)1.9 (−0.9 to 4.6)
 Change from placebo2.5 (−1.3 to 6.3)0.1 (−3.7 to 3.8)−0.7 (−4.5 to 3.1)2.1 (−1.7 to 5.9)
Non-HDL cholesterol
 % Change from baseline6.3 (2.2 to 10.4)6.1 (1.9 to 10.4)9.3 (5.2 to 13.4)8.2 (4.0 to 12.4)9.8 (5.6 to 14.0)
 Change from placebo−0.2 (−5.9 to 5.6)3.0 (−2.6 to 8.7)1.9 (−3.8 to 7.6)3.5 (−2.2 to 9.3)
Triglycerides
 % Change from baseline8.0 (−1.6 to 17.5)15.3 (6.0 to 24.6)27.6 (15.5 to 39.7)12.1 (3.4 to 20.8)18.2 (8.8 to 27.5)
 Change from placebo7.8 (−3.4 to 18.7)19.3 (7.2 to 31.2)*6.1 (−4.7 to 16.8)12.7 (1.9 to 24.3)**
Body weight (kg)
 Change from baseline−0.2 (−0.7 to 0.3)0.0 (−0.5 to 0.6)0.3 (−0.2 to 0.8)0.4 (−0.1 to 0.9)0.6 (0.1 to 1.1)
 Change from placebo0.2 (−0.5 to 0.9)0.5 (−0.2 to 1.2)0.6 (−0.1 to 1.3)0.8 (0.0 to 1.5)**
SBP (mmHg)
 Change from baseline−1.3 (−3.7 to 1.2)1.7 (−0.8 to 4.2)−1.2 (−3.6 to 1.2)0.8 (−1.7 to 3.3)2.5 (−0.1 to 5.0)
 Change from placebo3.0 (−0.4 to 6.4)0.1 (−3.2 to 3.4)2.0 (−1.3 to 5.4)3.7 (0.3 to 7.2)**
DBP (mmHg)
 Change from baseline−0.5 (−2.0 to 1.0)0.4 (−1.1 to 2.0)−1.0 (−2.5 to 0.5)0.5 (−1.0 to 2.0)0.8 (−0.8 to 2.3)
 Change from placebo1.0 (−1.1 to 3.0)−0.5 (−2.5 to 0.5)1.0 (−1.0 to 3.1)1.3 (−0.8 to 3.4)
  • Change from baseline or change from placebo data are expressed as LS mean change or LS mean percent change (95% CI) with LDA unless otherwise indicated.

  • †Data are median percent change (95% CI) using ANCOVA with last observation carried forward analysis; n per group ranged from 82 to 96 for triglycerides.

  • *P ≤ 0.001 for the between-group difference relative to placebo.

  • **P ≤ 0.05 for the between-group difference relative to placebo.